Hao-rui R. Shen

Nanjing, 210029, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications

R-MINE-containing regimen in relapsed and refractory diffuse large B-cell lymphoma: a single-arm, multicenter phase II study.

R-MINE-containing regimen in relapsed and refractory diffuse large B-cell lymphoma: a single-arm, multicenter phase II study.

Journal: BMC medicine
Published: March 25, 2026

Efficacy and safety analysis of BTK inhibitors combined with R-CHOP regimen in newly diagnosed double-expressor diffuse large B-cell lymphoma

Efficacy and safety analysis of BTK inhibitors combined with R-CHOP regimen in newly diagnosed double-expressor diffuse large B-cell lymphoma

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 16, 2026

Effect and safety of a conditioning regimen with chidamide and BEAM for autologous hematopoietic stem cell transplantation in lymphoma

Effect and safety of a conditioning regimen with chidamide and BEAM for autologous hematopoietic stem cell transplantation in lymphoma

Journal: Zhonghua nei ke za zhi
Published: December 03, 2025

Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.

Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.

Journal: BMC medicine
Published: October 30, 2025

Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial.

Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial.

Journal: Blood cancer journal
Published: June 10, 2025

BTG1 Mutation Correlates with Inferior Prognosis in Diffuse Large B-Cell Lymphoma.

BTG1 Mutation Correlates with Inferior Prognosis in Diffuse Large B-Cell Lymphoma.

Journal: Cancer research and treatment
Published: May 08, 2025

Prognostic Role of SOCS1 Mutations in Diffuse Large B-Cell Lymphoma.

Prognostic Role of SOCS1 Mutations in Diffuse Large B-Cell Lymphoma.

Journal: Cancer research and treatment
Published: April 14, 2025

Efficacy and safety of PEMD regimen in newly diagnosed early-stage non-upper respiratory digestive tract or advanced extranodal natural killer/T-cell lymphoma

Efficacy and safety of PEMD regimen in newly diagnosed early-stage non-upper respiratory digestive tract or advanced extranodal natural killer/T-cell lymphoma

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 26, 2025

Clinical implications of ctDNA-based minimal residual disease detection in newly diagnosed peripheral T-cell lymphoma: a single-center cohort study.

Clinical implications of ctDNA-based minimal residual disease detection in newly diagnosed peripheral T-cell lymphoma: a single-center cohort study.

Journal: Cell communication and signaling : CCS
Published: March 08, 2025

The efficacy and safety of thioamide in maintenance therapy for peripheral T-cell lymphoma

The efficacy and safety of thioamide in maintenance therapy for peripheral T-cell lymphoma

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: January 07, 2025

A Novel CD58 Mutation-Related Signature Predicts Prognosis Risk in Diffuse Large B-Cell Lymphoma Patients.

A Novel CD58 Mutation-Related Signature Predicts Prognosis Risk in Diffuse Large B-Cell Lymphoma Patients.

Journal: Cancer research and treatment
Published: November 27, 2024

SH3GL1-activated FTH1 inhibits ferroptosis and confers doxorubicin resistance in diffuse large B-cell lymphoma.

SH3GL1-activated FTH1 inhibits ferroptosis and confers doxorubicin resistance in diffuse large B-cell lymphoma.

Journal: Clinical and translational medicine
Published: October 21, 2024
Showing 1-12 of 34

Last Updated: 09/26/2026